← Browse by Condition
Medical Condition
follicular lymphoma
Total Trials
13
Recruiting Now
13
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Frequently Asked Questions — follicular lymphoma Clinical Trials
How many clinical trials are currently recruiting for follicular lymphoma?
ClinicalMetric currently tracks 13 actively recruiting clinical trials for follicular lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 13. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for follicular lymphoma?
follicular lymphoma research spans Phase 1 (4 trials), Phase 2 (7 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a follicular lymphoma clinical trial?
Eligibility criteria for follicular lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 4
Phase 2 7
Top Sponsors
2 trials
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07225439 Phase 1
Recruiting
Enrollment
15 pts
Location
United States
Sponsor
Paolo Caimi, MD
NCT06022029 Phase 1
Recruiting
Enrollment
168 pts
Location
United States, Austr...
Sponsor
OncoNano Medicine, Inc.
NCT06784167
Recruiting
Enrollment
45 pts
Location
United States
Sponsor
OHSU Knight Cancer Institute
NCT07299149 Phase 2
Recruiting
Enrollment
34 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
NCT03676504 Phase 1, Phase 2
Recruiting
Enrollment
68 pts
Location
Germany
Sponsor
University Hospital Heidelberg
NCT06563596 Phase 2
Recruiting
Enrollment
71 pts
Location
United States
Sponsor
Reid Merryman, MD
NCT05326308
Recruiting
Enrollment
845 pts
Location
Austria, Germany
Sponsor
iOMEDICO AG
NCT06151080 Phase 2
Recruiting
Enrollment
38 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT05541341
Recruiting
Enrollment
200 pts
Location
Brazil
Sponsor
Novartis Pharmaceuticals
NCT06826118 Phase 2
Recruiting
Enrollment
30 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT04186520 Phase 1, Phase 2
Recruiting
Enrollment
100 pts
Location
United States
Sponsor
Medical College of Wisconsin
NCT06830759
Recruiting
Enrollment
700 pts
Location
Argentina, Australia...
Sponsor
AbbVie
NCT05389293 Phase 2
Recruiting
Enrollment
152 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
Related Conditions
diffuse large b cell lymphoma (7) chronic lymphocytic leukemia (4) marginal zone lymphoma (4) mantle cell lymphoma (4) lymphoma (3) non hodgkin lymphoma (2) primary mediastinal large b cell lymphoma (2) small lymphocytic lymphoma (2) refractory lymphoma (2) b cell non hodgkin lymphoma (1) high grade b cell lymphoma (1) triple negative breast cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology